Prevalence of Periodontitis in Patients With Plaque Psoriasis. A Cross-sectional Study

• Conditions: Periodontitis; Psoriasis; Plaque Psoriasis; Periodontal Diseases
• Interventions: Diagnostic Test: Full periodontal chart; Other: Saliva sampling

• Registration Number: NCT04722094
• Lead Sponsor: University of Siena

Brief Summary

Psoriasis is a chronic inflammatory disease with a multi-factorial etiology which affects the epidermis and dermis. It affects around 1-3% of the general population and its most frequent form is plaque psoriasis (around 80-90% of the overall psoriasis cases). Psoriasis severity and extension are usually measured through 2 scores: Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA). Periodontitis is a chronic inflammatory disease mediated by the biofilm and with a multi-factorial etiology. Its manifestation entails the destruction of the periodontal tissues surrounding the teeth; the final stage of disease is characterised by tooth loss. Periodontitis severity and extension are usually evaluated through surrogate variables such as: BoP (Bleeding on Probing), PPD (Probing Pocket Depth) e REC (Recession). Both diseases present overlapping genetic and pathophysiologic features, as well as common risk factors (e.g. genetic polymorphisms, smoking habit, obesity, diabetes etc.).

miRNAs are small non-coding molecules involved in the regulation of various biologic processes thanks to their interaction with mRNAs. Active inflammatory processes either in the oral cavity or at a systemic level tend to alter the concentration of salivary miRNAs. No study so far has ever profiled the levels of specific salivary miRNAs in patients with psoriasis and periodontitis.

Some case-control studies highlighted a higher prevalence of periodontitis in patients with psoriasis when compared to healthy controls. Nonetheless, epidemiological data regarding periodontitis prevalence in patients with psoriasis are lacking; moreover, few data are available regarding the relationship between the severity of psoriasis and the severity of periodontitis, together with the effect of common risk factors (e.g. diet, obesity, physical activity, sleep quality etc.).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-01-19
• Study First Submitted QC: 2021-01-19
• Study Start: 2021-01-25
• Study First Posted: 2021-01-25
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-23
• Last Update Posted: 2021-02-24
• Primary Completion: 2021-06-25
• Study Completion: 2021-08-25

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 147

Inclusion Criteria

• Age between 18 and 70 years old
• Diagnosis of plaque psoriasis
• Ability and willingness to give informed consent

Exclusion Criteria

• Inability of unwillingness to give informed consent
• Pregnancy or lactation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with Psoriasis	Full periodontal chart	All patients pertaining to the Unit of Dermatology and affected by psoriasis will be screened for the inclusion in the study
Patients with Psoriasis	Saliva sampling	All patients pertaining to the Unit of Dermatology and affected by psoriasis will be screened for the inclusion in the study

Primary Outcome Measures

Name	Time	Method
Prevalence of Periodontitis in patients with Plaque psoriasis	Baseline	The prevalence of patients with a diagnosis of periodontitis among the included cohort will be measured.

Secondary Outcome Measures

Name	Time	Method
relationship between salivary miRNAs concentration and the severity of psoriasis and periodontitis	Baseline	salivary levels of miRNAs will be related to the severity of psoriasis and periodontitis

Trial Locations

Locations (1)

AOUS; 🇮🇹 Siena, Italy